Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study.
In a randomized, placebo-controlled study, we studied the effects of 4 months' treatment with rosiglitazone on low-grade inflammation, liver function, lipid levels, and blood pressure in 30 overweight women with polycystic ovary syndrome. Rosiglitazone significantly decreased serum C-reactive protein levels, white blood cell count, and alanine aminotransferase enzyme activity but did not affect lipid or blood pressure levels. Placebo had no effect on any parameters.
Rautio
Katrina
K
Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland.
Tapanainen
Juha S
JS
Ruokonen
Aimo
A
Morin-Papunen
Laure C
LC
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007249:Inflammation / Q000188:drug therapy*; D008107:Liver Diseases / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone